ClinicalTrials.gg
RecruitingNCT07853170Updated Oct 6, 2026

3-Needle vs 5-Needle of Genicular Nerve Block on Pain and Quality of Life in Knee Osteoarthritis

An interventional study of 3-nerve-targeted group and 5-nerve-targeted group in 3-Needle, 5-Needle and Genicular Nerve Block, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 6, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Pain by Tanta University — 10 open to participants now, 10 under way, 1 of them phase 3. Pain · Tanta University.

Planned enrollment
12th of 32
80 · median 70
Started
2026
with 4 others
No phase
30 of 32
9 open now
Registered
31st of 32
by date

Among the 32 studies in Pain by Tanta University, this one is the 12th largest by planned enrollment, is one of 5 that started in 2026, is one of 30 with no phase, and was the 31st registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

10 of the 32 studies in Pain by Tanta University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Pain by Tanta University, or all of them as a file.
02

Study summary

This study aims to compare the 3-needle and 5-needle of genicular nerve block on pain and quality of life in Knee osteoarthritis (KOA).

Read the detailed description

Knee osteoarthritis (KOA) is a common musculoskeletal disorder characterized by degeneration of articular cartilage and the subchondral bone. It leads to pain, stiffness, and functional decline in the affected knee joints.

Currently, the classical 3- nerve protocol targeting the superior medial, superior lateral, and inferior medial genicular nerves is the most commonly used technique for radiofrequency procedures.

Therefore, a five-needle Genicular nerve blocks (GNB) technique has been proposed to provide a more comprehensive blockade by targeting additional sensory branches.

03

Conditions studied

  • 3-Needle
  • 5-Needle
  • Genicular Nerve Block
  • Pain
  • Quality of Life
  • Knee Osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Both sexes.
  • Patients with unilateral chronic knee pain for more than 3 months.
  • Patients received conservative treatment for at least 3 months.
  • Diagnosed Knee osteoarthritis (KOA) according to the American College of Rheumatology (ACR) criteria, and grade greater than or equal to Kellgren-Lawrence grade 2.

Exclusion criteria

Exclusion Criteria:

  • Chronic knee pain is due to causes other than KOA, such as connective tissue diseases, lumbar radicular neuropathy (spondylolisthesis, spinal stenosis), or sciatic pain.
  • Knee effusion.
  • Neuro/psychiatric disorders.
  • History of intra-articular injection in the prior 3 months.
  • Prior knee surgery.
  • Active systemic or local knee infections; anticoagulant use.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Group I (3-nerve-targeted group)

    Patients will receive 3-nerve protocol.

    Other: 3-nerve-targeted group

  • Experimental
    Group II (5-nerve-targeted group)

    Patients will receive 5-nerve protocol.

    Other: 5-nerve-targeted group

Interventions

  • Other3-nerve-targeted group

    Patients will receive 3-nerve protocol.

  • Other5-nerve-targeted group

    Patients will receive 5-nerve protocol.

06

What researchers measure

Primary outcomes

  1. Degree of pain

    Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").

    Time frame: 6 months postoperatively

Secondary outcomes

  1. Measurement of Quality of life

    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered health status questionnaire and consists of 24 items divided into 3 subscales: pain (5 items), stiffness (2 items), and physical function (17 items). Accordingly, higher scores on the WOMAC indicate worse pain, stiffness, and functional limitation. The WOMAC will be assessed at each follow-up point

    Time frame: 6 months postoperatively

  2. Patients' opioid medication use

    Patients' opioid medication use will be evaluated before treatment and at 6 months after treatment.

    Time frame: 6 months after treatment

  3. Degree of patient satisfaction

    Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied)

    Time frame: 6 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Geng R, Li J, Yu C, Zhang C, Chen F, Chen J, Ni H, Wang J, Kang K, Wei Z, Xu Y, Jin T. Knee osteoarthritis: Current status and research progress in treatment (Review). Exp Ther Med. 2023 Aug 25;26(4):481. doi: 10.3892/etm.2023.12180. eCollection 2023 Oct. PubMed 37745043 ↗

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 10 months is close to that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 1, 2026
StartActual
Oct 4, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
Tanta University is now Recruiting
Oct 6, 2026
Start date
Oct 15, 2026→Oct 4, 2026 (actual)
Oct 6, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    Tanta University is now Recruiting
    Start date Oct 15, 2026→Oct 4, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853170
Lead sponsor
Tanta University
Responsible party
Mohammed Said ElSharkawy (Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Oct 1, 2026
Start date
Oct 4, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Mohammed S Elsharkawy, MD
Contact
mselsharkawy@med.tanta.edu.eg
00201148207870

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion